medigraphic.com

2006, Number 4

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2006; 44 (4)

Probability of Control of the Patient with Diabetes Exclusively Treated with Pharmacological Therapy

Villarreal-Ríos E, Paredes-Chaparro A, Martínez-González L, Galicia-Rodríguez L, Vargas-Daza E, Garza-Elizondo ME

Language: Spanish
References: 30
Page: 303-308
PDF size: 90.39 Kb.


ABSTRACT

Objective: to predict the probability of blood glucose control in patients with type-2 diabetes mellitus, exclusively treated with pharmacology therapy.
Material and methods: secondary analysis of a database to evaluate the therapeutic attachment in type-2 diabetics older than 60 years old. We interviewed 123 patients in their home to get information about sociodemographic aspects and diabetes characteristics. The blood glucose control was measured through glycated hemoglobin and the attachment to the pharmacological treatment was measured by the Morisky-Green test. The analysis included simple logistic regression; the calculation of probability of control for different levels of therapeutic attachment was estimated using the result of the regression equation (y) and applying the formula 1/1 + e–y.
Results: Monotherapy was present in 82.1 %, glibenclamide was prescribed alone in 77.2 %, glycated hemoglobin average was 11.5 ± 3.5 %, 18 % of the population was controlled and 58.1 % showed some attachment to the pharmaco-logical treatment. With a total attachment to the pharmacological prescription, the control pro-bability is 27 %, and without it, it corresponds to 10 %.
Conclusion: Almost three out of ten patients with a total attachment to the pharmacological treatment have chances of being controlled.


REFERENCES

  1. Murray CJ, López AD. Global mortality disability and the contribution of risk factors, global burden of disease study. Lancet 1997;349(9063):1436-1442.

  2. Olaiz G, Rojas R, Barquera S, Shamah T, Aguilar C, Cravioto P, López P, Hernández M, Tapia R, Sepúlveda J. Encuesta Nacional de Salud 2000. Tomo 2. La salud de los adultos. México: Instituto Nacional de Salud Pública; 2003.

  3. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson ChM, Sacks DB. Tests of glycemia in diabetes. Diabetes Care 2004;27(7): 1761-1773.

  4. Rush W, O’Connor P. Validation of an automated medication adherence measure for diabetes pa-tients. Diabetes 2002;51(Suppl 2):A76.

  5. Donnan P, Steinke D, Newton R, Morris A. Changes in treatment after the start of oral hypoglycaemic therapy in type 2 diabetes: a population-based study. Diabet Med 2002;19(7):606-610.

  6. Rizkalla SW, Taghrid L, Laromiguiere M, Huet D, Boillot J, Rigoir A, Elgrably F, Slama G. Improved plasma glucose control, whole-body glucose utilization, and lipid profile on a low-glycemic index diet in type 2 diabetic men: a randomized controlled trial. Diabetes Care 2004:27(8):1866-1872.

  7. American Diabetes. Association diabetes mellitus and exercise. Diabetes Care 2002;(Suppl 1):S64-S68.

  8. Norris S, Engelgau M, Narayan K. Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Care 2001; 24(3):561-587.

  9. Norma oficial mexicana NOM-015-SSA2-1994 para la prevención, tratamiento y control de la diabetes. Disponible en: http://www.salud.gob.mx/unidades/cdi/nom/m015ssa24.html

  10. Kim H, Oh J. Adherence to diabetes control recommendations: impact of nurse telephone calls. J Adv Nurs 2003;44(3):256-261.

  11. Rodríguez M. Importancia del apoyo familiar en el control de la glucemia, Salud Publica Mex 1997; 39:44-47.

  12. Martín-Reyes F, Rodríguez-Morán M. Apoyo fa-miliar en el apego al tratamiento de la hipertensión arterial esencial. Salud Publica Mex 2001;43:336-339.

  13. Evans J, Donnan P, Morris A. Adherence to oral hypoglycaemic agents prior to insulin therapy in Type 2 diabetes. Diabet Med 2002; 19(8):685-688.

  14. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004;27(12):2800-2805.

  15. McNabb W. Adherence in diabetes: can we define it and can we measure it? Diabetes Care 1997;20(2): 215-218.

  16. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care 1986;24:67-74.

  17. Liu H, Golin C, Miller L, Hays R, Beck C, Sanandaji S, Christian J. Maldonado T, Duran D, Kaplan A, Wenger N. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001;134(10):968-977.

  18. Morningstar B, Sketris I, Kephart G, Sclar D. Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther 2002;27(3):213-220.

  19. Piñeiro-Chousa F, Gil-Guillén VF, Donis-Otero M, Orozco-Beltrán D, Pastor-López R, Merino-Sánchez J. Validez de seis métodos indirectos para valorar el cumplimiento del tratamiento farmacológico en la diabetes no insulinodependiente. Rev Clin Esp 1997;197:555-559.

  20. Piñeiro F, Gil V, Donis M, Orozco D, Pastor R, Merino J. Validez de seis métodos indirectos para valorar el cumplimiento del tratamiento farmacológico en la hipertensión arterial. Atencion Primaria 1997; 19:372-376.

  21. Coon P, Zulkowski K. Adherence to American Diabetes Association standards of care by rural health care providers. Diabetes Care 2002;25(12): 2224-2229.

  22. American Diabetes Association. Normas para el cuidado médico de pacientes con diabetes mellitus. Diabetes Care 1999;Suppl 1;s32-s41.

  23. American Diabetes Association. Pruebas de glucemia en diabetes. Diabetes Care 1999;Suppl 1;s77-s79.

  24. De Sonnaville J, Snoek F, Colly L, Wijkel W, Heine R. Well-being and symptoms in relation to insulin therapy in type II diabetes. Diabetes 1998;47 (Suppl 1):323A.

  25. Evans J, Donnan P, Morris A. Adherence to oral hypoglycaemic agents in type 2 diabetes: is this a predictor of insulin requirement? Diabet Med Supplement 2001;18(Suppl 2):8.

  26. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004;64(12):1339-1358.

  27. Davidson J, Scheen A, Howlett H. Tolerability profile of metformin/glibenclamide combination tablets [glucovance(R)]: a new treatment for the management of type 2 diabetes mellitus. Drug Safety 2004;27(15):1205-1216.

  28. Donnan P, MacDonald T, Morris A. Adherence to prescribed oral hypoglycaemic medication in a popu-lation of patients with type 2 diabetes: a retros-pective cohort study. Diabetic Medicine 2002;19(4): 279-284.

  29. Morris A, Brennan G, MacDonald T, Donnan P. Population-based adherence to prescribed medication in type 2 diabetes: a cause for concern. Diabetes 2000;49(Suppl 1):A76.

  30. Villarreal-Ríos E, Salinas-Martínez AM, Medina-Jáuregui A, Garza-Elizondo ME, Núñez-Rocha GM, Chuy-Díaz E. The cost of diabetes mellitus and its impact on health spending in Mexico. Arch Med Res 2000;31:511-514.




2020     |     www.medigraphic.com